Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bo-Er-Ning capsule (BENC) is a traditional Chinese herbal medicine (CHM) formulation derived from an 11-herb prescription, approved in China as a patent herbal drug (PHD) for the adjuvant treatment of cancer. It is primarily utilized as an add-on therapy to standard chemotherapy regimens, such as the FP (tegafur and cisplatin) or CF (cisplatin and fluorouracil) regimens, specifically for patients with advanced (stage IV) gastric cancer. Clinical evaluations have demonstrated that BENC add-on therapy can improve quality of life, Karnofsky performance scores, and overall survival compared to chemotherapy alone. Mechanistically, bioinformatics and enrichment analyses suggest that BENC modulates cell proliferation, induces cell cycle arrest, and promotes apoptosis by regulating key proteins including Bcl-2, Bax, and caspase-9.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bo-Er-Ning capsule.